AU1543797A - Process for preparing purine derivatives - Google Patents

Process for preparing purine derivatives

Info

Publication number
AU1543797A
AU1543797A AU15437/97A AU1543797A AU1543797A AU 1543797 A AU1543797 A AU 1543797A AU 15437/97 A AU15437/97 A AU 15437/97A AU 1543797 A AU1543797 A AU 1543797A AU 1543797 A AU1543797 A AU 1543797A
Authority
AU
Australia
Prior art keywords
preparing
purine derivatives
intermediates
preparing purine
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15437/97A
Inventor
Humberto B. Arzeno
Steven D. Axt
Colin C. Beard
Charles A. Dvorak
Paul R. Fatheree
Lawrence E. Fisher
Yeun-Kwei Han
Eric R Humphreys
Jan P. Lund
Sam Linh Nguyen
Douglas Leslie Wren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU1543797A publication Critical patent/AU1543797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Process and novel intermediates for preparing the L-monovaline ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process and intermediates provide for reduced impurities in the mono-valine ester end-product, also eliminating the costly and time consuming purification step and allowing the use of starting materials of lower purity, which, in turn, reduces overall production costs. These products are of value as antiviral agents with improved absorption.
AU15437/97A 1996-01-26 1997-01-21 Process for preparing purine derivatives Abandoned AU1543797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59207996A 1996-01-26 1996-01-26
US592079 1996-01-26
PCT/EP1997/000262 WO1997027198A1 (en) 1996-01-26 1997-01-21 Process for preparing purine derivatives

Publications (1)

Publication Number Publication Date
AU1543797A true AU1543797A (en) 1997-08-20

Family

ID=24369197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15437/97A Abandoned AU1543797A (en) 1996-01-26 1997-01-21 Process for preparing purine derivatives

Country Status (10)

Country Link
JP (1) JP4094667B2 (en)
KR (1) KR100491941B1 (en)
CN (1) CN1064683C (en)
AT (1) ATE222909T1 (en)
AU (1) AU1543797A (en)
CA (1) CA2243650C (en)
DE (1) DE69714971T3 (en)
ES (1) ES2180923T5 (en)
MX (1) MX9805935A (en)
WO (1) WO1997027198A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
WO2005023827A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
WO2012163373A1 (en) * 2011-05-31 2012-12-06 Pharmathen S.A. Process for the preparation of 2-amino-9-((2-phenyl-1,3-dioxan-5-yloxy)methyl)-1h-purin-6(9h)-one compound useful in the preparation of valganciclovir

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
NL8202626A (en) * 1982-06-29 1984-01-16 Stichting Rega V Z W DERIVATIVES OF 9- (2-HYDROXYETHOXYMETHYL) GUANINE.
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE68922903T2 (en) * 1988-12-19 1995-11-23 Wellcome Found Antiviral pyrimidine and purine compounds, processes for their preparation and pharmaceutical preparations containing them.
JP3225545B2 (en) * 1991-09-18 2001-11-05 味の素株式会社 Method for producing acyclic nucleosides
PE32296A1 (en) * 1994-07-28 1996-08-07 Hoffmann La Roche L-MONOVALINE ESTER DERIVED FROM 2- (2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-IL) METOXI-1,3-PROPANDIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

Also Published As

Publication number Publication date
CA2243650A1 (en) 1997-07-31
ATE222909T1 (en) 2002-09-15
ES2180923T5 (en) 2005-10-16
CA2243650C (en) 2006-08-15
ES2180923T3 (en) 2003-02-16
CN1212693A (en) 1999-03-31
JP2000503977A (en) 2000-04-04
DE69714971T3 (en) 2005-12-15
JP4094667B2 (en) 2008-06-04
WO1997027198A1 (en) 1997-07-31
KR100491941B1 (en) 2005-08-05
CN1064683C (en) 2001-04-18
MX9805935A (en) 1998-11-30
DE69714971D1 (en) 2002-10-02
DE69714971T2 (en) 2003-05-28
KR19990081991A (en) 1999-11-15

Similar Documents

Publication Publication Date Title
CA2244680A1 (en) Process for preparing purine derivatives
MY114393A (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivatives
MD1155B2 (en) Diastereoselective processes for production of optically active cis-nucleosides, analogues and derivative nucleosides, intermediates and processes for production thereof The present invention relates to highly diastereoselective processes for production of optically active cis-nucleosides, nucleoside analogues and derivatives and intermediates useful in thos The technical result consists in increasing the yield of highly pure and optically active cis-nucleosides. Claims: 34
AU6212596A (en) Process for the production of high purity carbon dioxide
EP0400472A3 (en) Process for preparing polyethylene glycol derivatives and modified protein.
AU3105793A (en) Process for purifying acrylic acid in high purity in the production of acrylic acid
PT86074A (en) Process for preparing new substituted cephalosporin sulfones as anti-inflammatory and antidegenerative agents
FI98067B (en) Novel alkylenediammonium diclavulanate derivatives, process for their preparation as well as their use for the purification of calvulanic acid
AU1543797A (en) Process for preparing purine derivatives
AU3407093A (en) Process for the production of pharmaceutically acceptable salts of clavulanic acid
AU3420099A (en) Process for the production of purine derivatives and intermediates therefor
HUT42078A (en) Process for preparing benzoxazine derivatives applicable in the production of herbicides as intermediates
EP0249247A3 (en) Purine derivatives
AU7321900A (en) Process for the production of aspartyldipeptide ester derivatives, novel intermediates therefor and process for the production of the intermediates
EP0347777A3 (en) Process for preparing cephalosporins and intermediates therefor
CA2322231A1 (en) Process for the purification of s-adenosyl-l-methionine and for the preparation of the pharmaceutically acceptable salts thereof
AU4613100A (en) Process for producing optically active azetidine-2-carboxylic acids
AU1723792A (en) Preparation of alkanesulfonamides
EP1000933A4 (en) Trifluoro methylthiomethyl benzene derivatives and process for producing the same
FI103885B (en) Process for the preparation of therapeutically active 1-benzyl-4-phenylpiperazine derivatives and the compounds useful in intermediates
HUT53652A (en) New process for producing 3-exomethylene cefamsulfoxide derivatives and 2-chlorosulfinyl azetidin-4-ones
JPS6442489A (en) Method for crystallization and purification of 7-acylamidodeacetoxycephalosporanic acid
AU3191700A (en) Process for producing 5-amino-8- alkylquinolo necarboxylic acid derivatives and intermediates in the production thereof
JPS642796A (en) Laser beam machine
HU9700657D0 (en) Process for producing 3-cyano-steroide derivatives as intermediates of pharmaceutically active steroide derivatives